NASDAQ: JUNO) has inked three license agreements to advance its programme in multiple myeloma using gamma secretase
inhibitors in combination with BCMA-directed CAR T cells, the company said.
announced today that the latest data on its oral dual orexin receptor antagonist lemborexant and its oral beta secretase
cleaving enzyme (BACE) inhibitor elenbecestat will be presented at the 10th Clinical Trials on Alzheimer's Disease (CTAD), taking place in Boston, the United States, from November 1 to 4.
The compound deters beta secretase
enzyme BACE 1 related to the create of beta amyloid.
announced today that enrollment has commenced in MISSION AD, a Phase III clinical program of the beta secretase
cleaving enzyme (BACE) inhibitor E2609 in patients with early Alzheimer's disease in the United States.
An important number of the mutations occur at the secretase
cleavage site or in the transmembrane domain.
With regard to APP intracellular processing, both secretases
([alpha]- and [beta]-) have been identified in the ER together with [gamma]-secretase
which is present in mitochondria-associated membrane (MAM) subcompartment [48, 68].
Research over the last few years indicates that a misregulation of the secretase
cleavage in Alzheimer's results in inadequate production of protective APPsα.
and AstraZeneca have entered an agreement to co-develop and commercialize AZD3293, an oral beta secretase
cleaving enzyme (BACE) inhibitor in development as a potential treatment for Alzheimer's disease (AD).
Both the AstraZeneca and Merck medicines work by blocking an enzyme called beta secretase
that is involved in production of beta-amyloid, a protein that creates brain plaques considered a major cause of Alzheimer's disease.
Discovery of the [beta]- and [gamma]-secretase
substrates calls for precaution concerning the anti-A[beta] production strategy targeted at the secretases
: chronic and over-inhibition of the secretases
is likely to cause adverse side-effects.
Identification of two novel synaptic gamma- secretase
associated proteins that affect amyloid beta-peptide levels without altering Notch processing.
Recent research has revealed mutations at what is called the 'beta secretase
site'--the point where BACE1 cuts the amyloid precursor," says Dr.